logo
  

3D Systems To Buy Cimatron For $8.97 Per Share - Quick Facts

3D Systems Corp. (DDD) Monday said it will acquire Cimatron Ltd. (CIMT), a provider of 3D CAD/CAM software for the manufacturing industry, for $97 million or $8.97 per share in cash. The acquisition would strengthen the company's position in the 3D design and manufacturing space, as well as extend its direct and reseller sales coverage worldwide.

The transaction, which is anticipated to close in the first quarter of 2015, is expected to immediately add to the group's cash generation and non-GAAP earnings per share, upon closing.

"We believe that the perfect strategic fit between our businesses, combined with expanded capabilities in product development, channel coverage and marketing, could present sizeable synergies that together offer significant long-term customer benefits and shareholder value," said Avi Reichental, CEO of 3DS.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT